Patterns of Pregabalin Users from Substance Abuse Treatment Facilities: Results from the French OPPIDUM Program from 2008 to 2022 (vol 38, pg 743, 2024)

被引：0

作者：

Garnier, Clement ^{[1
,2
]}

Schein, Martin ^{[1
,2
]}

Lacroix, Clemence ^{[1
]}

Jouve, Elisabeth ^{[1
]}

Soeiro, Thomas ^{[1
]}

Gentile, Gaetan ^{[2
]}

Lapeyre-Mestre, Maryse ^{[3
]}

Micallef, Joelle ^{[1
]}

机构：

[1] Aix Marseille Univ, Univ Hosp, Inst Neurosci Syst,UMR 1106,Serv Pharmacol Clin &, Ctr Evaluat & Informat Pharmacodependance Addictov, 270 Blvd Sainte Marguer, F-13009 Marseille, France

[2] Dept Univ Med Gen, Fac Sci Med & Paramed, Marseille, France

[3] UFR Sante Univ Toulouse Paul Sabatier, CHU Toulouse, Serv Pharmacol Med & Clin, CEIP Addictovigilance Toulouse,CIC 1436, F-31000 Toulouse, France

来源：

CNS DRUGS | 2024年 / 38卷 / 10期

关键词：

D O I：

10.1007/s40263-024-01119-7

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

引用

页码：839 / 839

页数：1

共 36 条

[31] IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. (vol 67, pg 1516, 2008)
Emery, P.
Keystone, E.
Tony, H. P.
Cantagrel, A.
van Vollenhoven, R.
Sanchez, A.
ANNALS OF THE RHEUMATIC DISEASES, 2009, 68 (02) : 296 - 296
[32] Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial (vol 23, pg 888, 2022)
Motzer, R. J.
Powles, T.
Burotto, M.
LANCET ONCOLOGY, 2022, 23 (07): : E319 - E319
[33] Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial (vol 23, pg 888, 2022)
Vergote, I
Gonzalez-Martin, A.
Lorusso, D.
LANCET ONCOLOGY, 2022, 23 (09): : E404 - E404
[34] Treatment Patterns, Safety, and Patient-Reported Outcomes among Adult Women with Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer with or without Unknown BRCA1/2 Mutation(s): Results of a Real-World Study from the United States, United Kingdom, and Four EU Countries (vol 17, pg 460, 2022)
Lux
BREAST CARE, 2022, 17 (04) : 437 - 437
[35] Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as secondline treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial (vol 399, pg 2294, 2022)
Kamdar, M.
Solomon, S. R.
Arnason, J.
LANCET, 2022, 400 (10347): : 160 - 160
[36] Evaluating the Supportive Care Costs of Severe Radiochemotherapy-Induced Mucositis and Pharyngitis: Results From a Northwestern University Costs of Cancer Program Pilot Study With Head and Neck and Nonsmall Cell Lung Cancer Patients Who Received Care at a County Hospital, a Veterans Administration Hospital, or a Comprehensive Cancer Care Center (vol 113, pg 1446, 2008)
Nonzee, N. J.
Dandade, N. A.
Markossian, T.
Agulnik, M.
Argiris, A.
Patel, J. D.
Kern, R. C.
Munshi, H. G.
Calhoun, E. A.
Bennett, C. L.
CANCER, 2009, 115 (12) : 2805 - 2805

← 1 2 3 4 →